TempraMed to Commence Trading on the Canadian Securities Exchange Under Symbol "VIVI", Today, October 15, 2025

Executive Summary

• TempraMed Technologies Ltd. received approval to list its common shares on the Canadian Securities Exchange (CSE) under the ticker “VIVI,” with trading slated to begin at market open on October 15, 2025.
• The board accepted the resignation of Director Ran Enoch effective October 10, 2025.
• Julia Becker was appointed as a new director, also assuming the role of Vice President, Capital Markets, effective October 10, 2025.

Key Details

• Listing Approval: CSE granted permission for TempraMed’s common shares to be listed; trading will commence on the CSE at market open on 15 Oct 2025 under symbol “VIVI.”
• Resignation: Director Ran Enoch resigned from the board, effective 10 Oct 2025. The Board thanked him for his service.
• Appointment: Julia Becker appointed as a director and Vice President, Capital Markets, effective 10 Oct 2025. She is founder & President of Strike Communications Inc., with 15 years of experience in investor relations and capital‑markets strategy across multiple sectors.
• Contact Information:
• CEO: Ron Nagar – [email protected]
• New Director/VP Capital Markets: Julia Becker – [email protected], +1 (604) 785‑0850
• Forward‑Looking Statements: The release contains forward‑looking statements regarding the listing and future operations; standard risk disclosures apply.

Notable Quotes

(No direct quotes were provided in the release.)